Retatrutide

Retatrutide (GIP/GLP-1/glucagon triple agonist) is a triple hormone receptor agonist. The HEIVE catalog describes it as: One molecule on three metabolic receptors. Phase 3 put mean loss at 28.3% over 80 weeks — the largest figure any drug has produced short of surgery. Still investigational. It is also known as LY3437943.

HEIVE groups Retatrutide under appetite, glycemic control, body recomposition, fat distribution and keeping the result. These catalog categories are not approved indications or evidence that treatment works. See the product-specific regulatory answer below.

No. Lilly describes retatrutide as investigational and not approved by any regulatory agency in its September 2026 update. Lilly states it is available only to participants in its clinical trials. No approval or public-access date is established here.

• FDA product data (October 6, 2026)
• Lilly retatrutide update (September 2026)

The HEIVE editorial risk summary for Retatrutide lists: Nausea, vomiting, constipation — dose-dependent and worst during escalation. Longer-term concerns: Still investigational. Heart-rate elevation, and the same muscle-loss question as every incretin. This is not a complete or clinically reviewed safety assessment; risks depend on the product, route and population.

Retatrutide has no single onset time established by this catalog. The editorial timeline starts with “Weeks 1–4”. These are illustrative model or editorial milestones, not clinically validated outcome predictions.

HEIVE's illustrative catalog entry for Retatrutide: 2 mg weekly, escalating every four weeks toward 4–12 mg. This is not a verified study range or a prescription. A dose cannot be transferred between products, routes or indications; use the specific approved label and the prescribing clinician's instructions where applicable.

The catalog classifies Retatrutide as having human research. Its paper-count snapshot is not a live PubMed search, a count of controlled human trials or proof of safety. This FAQ has not independently validated the catalog's clinical literature claims.

The source catalog lists only injectable forms for Retatrutide; it does not establish that every studied or marketed form is injectable.

Preparation of Retatrutide depends on the exact labeled product. Follow its instructions for formulation, diluent, route and storage. A generic powder recipe must not be applied to a prefilled, ready-to-use or differently formulated product. The catalog's mixing example does not establish sterility or stability.

Storage for Retatrutide depends on the specific formulation (injectable in the source catalog). Follow the product's labeled temperature, light protection and expiry or discard instructions. A general refrigerator or 28-day rule does not establish stability or sterility for every preparation.

The HEIVE editorial summary for Retatrutide: None described. Escalation is scheduled, not adaptive. This summary is not a clinically validated prediction of tolerance or withdrawal for an individual.

Retatrutide and Semaglutide share the catalog categories appetite, glycemic control and body recomposition. Retatrutide: One molecule on three metabolic receptors. Phase 3 put mean loss at 28.3% over 80 weeks — the largest figure any drug has produced short of surgery. Still investigational. Semaglutide: The most rigorously trialled molecule in this library, with cardiovascular outcome data behind it. This is a catalog comparison, not a head-to-head clinical result or a recommendation to substitute treatments.

• View Semaglutide

The HEIVE editorial summary highlights: Liver-fat clearance in trial subgroups outran what the weight loss alone could explain. The cited study, population and formulation must be checked before treating this summary as a clinical finding; this FAQ does not supply a verified research citation for it.